Cytovance Biologics Enhances Biologics Manufacturing Process Development with Perfusion Capabilities to Boost Productivity

July 19, 2026

Cytovance Biologics USA

Overview

Cytovance Biologics, a CDMO, has expanded its upstream process development services by integrating perfusion capabilities. This technological addition enables higher productivity, extended cell culture durations, and improved process consistency for the manufacturing of monoclonal antibodies, recombinant proteins, and other biologics, offering an alternative to traditional fed-batch methods. The aim is to provide more flexible and efficient manufacturing solutions to biopharmaceutical companies, thereby accelerating program success.

In Depth

Key Findings

Cytovance Biologics, a contract development and manufacturing organization (CDMO) for biologics, has significantly enhanced its upstream process development services by incorporating perfusion capabilities. This strategic augmentation allows the company to offer advanced solutions to clients, enabling higher productivity, extended cell culture durations, and improved process consistency for the manufacturing of monoclonal antibodies, recombinant proteins, and other complex biologics.

Technical & Clinical Details

Perfusion culture is a technique that continuously exchanges cell culture media while retaining cells within the bioreactor. This method permits the maintenance of significantly higher cell densities compared to traditional fed-batch cultures, leading to a dramatic increase in volumetric productivity. By producing equivalent or greater amounts of product in smaller bioreactor volumes, perfusion contributes to reduced manufacturing costs and increased efficiency. Furthermore, its ability to sustain cell cultures for longer periods enhances process consistency and offers greater flexibility in manufacturing schedules. Cytovance’s newly integrated perfusion system is designed to accommodate a wide range of biopharmaceutical programs, supporting development from early-stage process optimization to commercial-scale production.

Background & Context

With the rapid expansion of the biopharmaceutical market, drug developers are increasingly seeking more efficient and cost-effective manufacturing processes from CDMOs. The growing complexity of new modalities and the demand for accelerated time-to-market often challenge the capabilities of traditional fed-batch processes. Perfusion culture is particularly advantageous for producing high-titer, complex biological products, as it aids in reducing manufacturing footprints, optimizing capital expenditure, and facilitating faster market supply. Consequently, it has gained significant attention and adoption within the industry.

Strategic Significance & Outlook

The integration of perfusion capabilities by Cytovance Biologics is expected to bolster its competitive edge and strengthen its position as a leading CDMO in biologics manufacturing. This new technology will provide clients with greater flexibility and efficiency throughout their product development lifecycle, particularly smoothing the transition from small-scale early-stage production to commercial volumes. This is a critical factor in accelerating the market entry of diverse biopharmaceuticals, including antibodies, recombinant proteins, and next-generation cell and gene therapy products. Cytovance plans to continue adopting state-of-the-art manufacturing technologies to support the growth of the biopharmaceutical industry.

Source: https://cytovance.com/news-articles/expanded-process-development-services-with-perfusion/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.